AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17525387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA) started at 0.6 mg/kg over 30 minutes, followed by additional rt-PA via EKOS micro-infusion catheter or standard microcatheter up to a total dose of 22 mg over 2 hours.
Number of subjects: 81
Study 17525387 — intervention group
Group type: COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 81
Study 17525387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous and intra-arterial approach
Number of subjects: 81
Study 15453848 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL (SI40NB, Allergan)
Number of subjects: 119
Study 15453848 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IOL (MA60BM, Alcon)
Number of subjects: 119
Study 11584084 — intervention group
Group type: COMPARATOR
Intervention: High folate diet
Number of subjects: 37
Study 11584084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low folate diet
Number of subjects: 37
Study 9706855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine mouthrinse (0.1%)
Number of subjects: 42
Study 9706855 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 42
Study 7886652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (20 micrograms/puff)
Number of subjects: 20
Study 7886652 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutropium bromide (30 micrograms/puff)
Number of subjects: 20
Study 7886652 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (100 micrograms/puff)
Number of subjects: 20
Study 7886652 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms/puff)
Number of subjects: 20
Study 7886652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2190927 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg quotid. enalkiren
Number of subjects: 32
Study 2190927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg q.i.d. enalkiren
Number of subjects: 32
Study 2190927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27828 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienodiazepine (clotiazepam)
Number of subjects: 40
Study 27828 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no treatment not explicitly mentioned)
Number of subjects: 40
Study 31814140 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth application for wound care
Number of subjects: 70
Study 31814140 — intervention group
Group type: COMPARATOR
Intervention: Verbal instructions and a booklet (Control)
Number of subjects: 70
Study 30707210 — intervention group
Group type: EXPERIMENTAL
Intervention: Early protocolized rehabilitation (consultation of physical therapy, occupational therapy, and speech and language therapy within 72 hours of ICU admission, n = 26)
Number of subjects: 58
Study 30707210 — intervention group
Group type: COMPARATOR
Intervention: Usual care (consultation per treating team, n = 32)
Number of subjects: 58
Study 30707210 — intervention group
Group type: EXPERIMENTAL
Intervention: Early protocolized rehabilitation
Number of subjects: 58
Study 26059899 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 supplementation (100 IU/kg daily)
Number of subjects: 50
Study 26059899 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 supplementation (100 IU/kg daily)
Number of subjects: 50
Study 26059899 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 IU/kg daily)
Number of subjects: 50
Study 26059899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (D2 and D3)
Number of subjects: 50
Study 25317722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral application of 5 mL CHX 0.12% solution before intubation
Number of subjects: 314
Study 25317722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHX before intubation)
Number of subjects: 314
Study 23688526 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 1234
Study 23688526 — intervention group
Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 1234
Study 21828387 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% menthol gel
Number of subjects: 17
Study 21828387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice (0.5 kg)
Number of subjects: 17
Study 21828387 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 17
Study 19903643 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) followed by low-level diode laser treatment for 5 days (Group B)
Number of subjects: 60
Study 19903643 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) followed by low-level diode laser treatment for 10 days (Group C)
Number of subjects: 60
Study 19903643 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) on a single quadrant per day for four consecutive days, followed by rescaling on the fifth day (Group A)
Number of subjects: 60
Study 17100678 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 66
Study 12831591 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG
Number of subjects: 10
Study 12831591 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH
Number of subjects: 10
Study 9921711 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (aim: aPTT approximately 2 x normal)
Number of subjects: 56
Study 9921711 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 56
Study 8677862 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749
Study 8677862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study 1984373 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg
Number of subjects: 40
Study 1984373 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 40
Study 1984373 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 4 mg/kg
Number of subjects: 40
Study 1984373 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 6.5 mg/kg
Number of subjects: 40
Study 6412673 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of sodium cromoglycate (SCG) aerosol
Number of subjects: 15
Study 6412673 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of sodium cromoglycate (SCG) aerosol
Number of subjects: 15
Study 6412673 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 4 mg of sodium cromoglycate (SCG) aerosol
Number of subjects: 15
Study 6412673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3894841 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine dimesilate 36 mg daily for at least six weeks
Number of subjects: 40
Study 29291739 — intervention group
Group type: EXPERIMENTAL
Intervention: KM2H2 plus standard care
Number of subjects: 450
Study 29291739 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 450
Study 27739262 — intervention group
Group type: EXPERIMENTAL
Intervention: Carica papaya leaf extract (CPLE) administered three times daily for five days
Number of subjects: 300
Study 27739262 — intervention group
Group type: COMPARATOR
Intervention: Standard management guidelines for dengue (Control group)
Number of subjects: 300
Study 24674234 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX), N=61
Number of subjects: 85
Study 24674234 — intervention group
Group type: COMPARATOR
Intervention: Placebo, N=24
Number of subjects: 85
Study 23183732 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls in school
Number of subjects: 665
Study 23183732 — intervention group
Group type: COMPARATOR
Intervention: Girls not in school
Number of subjects: 665
Study 20530518 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of dalteparin
Number of subjects: 8
Study 20530518 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose of dalteparin
Number of subjects: 8
Study 20530518 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 8
Study 19002344 — intervention group
Group type: EXPERIMENTAL
Intervention: acitretin-narrow-band TL-01 phototherapy
Number of subjects: 60
Study 19002344 — intervention group
Group type: COMPARATOR
Intervention: acitretin-psoralen plus ultraviolet A (acitretin-PUVA)
Number of subjects: 60
Study 16169400 — intervention group
Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (LAC) 3 g/d
Number of subjects: 60
Study 16169400 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined L-carnitine (LC) 2 g/d and L-acetylcarnitine (LAC) 1 g/d
Number of subjects: 60
Study 16169400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12501022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 5
Study 10655964 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate by inhalation (2 puffs of aerosol containing 1 mg per delivery, total 2 mg over 3 months)
Number of subjects: 25
Study 10655964 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol without retinyl palmitate
Number of subjects: 25
Study 8910235 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh)
Number of subjects: 8
Study 8910235 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine vehicle
Number of subjects: 8
Study 8910235 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) vehicle
Number of subjects: 8
Study 1715478 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrendipine 10 mg b.i.d. (n = 39)
Number of subjects: 78
Study 1715478 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrendipine 20 mg o.d. (n = 39)
Number of subjects: 78
Study 1715478 — intervention group
Group type: COMPARATOR
Intervention: nitrendipine 10 mg b.i.d. (n = 32)
Number of subjects: 78
Study 1715478 — intervention group
Group type: COMPARATOR
Intervention: nitrendipine 20 mg o.d. (n = 28)
Number of subjects: 78
Study 1715478 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrendipine 20 mg o.d.
Number of subjects: 78
Study 1715478 — intervention group
Group type: COMPARATOR
Intervention: nitrendipine 10 mg b.i.d.
Number of subjects: 78
Study 6358177 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienamycin formamidine/renal dipeptidase inhibitor
Number of subjects: 21
Study 6358177 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 21
Study 30268384 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 12
Study 30268384 — intervention group
Group type: COMPARATOR
Intervention: Ischemia-reperfusion without intervention
Number of subjects: 12
Study 30268384 — intervention group
Group type: EXPERIMENTAL
Intervention: iv administration of GLP-1 receptor antagonist exendin(9-39) + ischemia-reperfusion + RIC
Number of subjects: 12
Study 29073347 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Number of subjects: 306
Study 29073347 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 306
Study 29073347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 26797875 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel disposable suture device
Number of subjects: 582
Study 26797875 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture approach
Number of subjects: 582
Study 24599566 — intervention group
Group type: EXPERIMENTAL
Intervention: epinephrine plus 1% lidocaine hydrochloride (group B)
Number of subjects: 42
Study 24599566 — intervention group
Group type: COMPARATOR
Intervention: epinephrine only (group A)
Number of subjects: 42
Study 22160637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 403
Study 22160637 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 403
Study 19672937 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery-related mortality
Number of subjects: 15614
Study 19672937 — intervention group
Group type: EXPERIMENTAL
Intervention: Total morbidity
Number of subjects: 15614
Study 19672937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile leakage
Number of subjects: 15614
Study 19672937 — intervention group
Group type: EXPERIMENTAL
Intervention: Postresectional liver failure
Number of subjects: 15614
Study 19672937 — intervention group
Group type: COMPARATOR
Intervention: Operative mortality
Number of subjects: 15614
Study 17426331 — intervention group
Group type: EXPERIMENTAL
Intervention: HAES group
Number of subjects: 144
Study 17426331 — intervention group
Group type: EXPERIMENTAL
Intervention: SS group
Number of subjects: 144
Study 17426331 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 15781339 — intervention group
Group type: COMPARATOR
Intervention: HSCT recipients
Number of subjects: 139
Study 12148881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic doses of nadroparin (Fraxiparine)
Number of subjects: 46
Study 12148881 — intervention group
Group type: COMPARATOR
Intervention: No heparin prophylaxis (Control)
Number of subjects: 46
Study 10589004 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 100 microg/d
Number of subjects: 323
Study 10589004 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 microg/d
Number of subjects: 323
Study 10589004 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 800 microg/d
Number of subjects: 323
Study 10589004 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP 100 microg/d
Number of subjects: 323
Study 10589004 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP 400 microg/d
Number of subjects: 323
Study 10589004 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP 800 microg/d
Number of subjects: 323
Study 8934250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (NAF)
Number of subjects: 0
Study 8934250 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate (LA)
Number of subjects: 0
Study 1855751 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytodolor N (3 x 30 drops daily for 3 weeks)
Number of subjects: 40
Study 1855751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6338683 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 6338683 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 11
Study 6338683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31615057 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical Korean Diet (TKD)
Number of subjects: 0
Study 31615057 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended American Diet (RAD)
Number of subjects: 0
Study 31615057 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical American Diet (TAD)
Number of subjects: 0
Study 29684979 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported exercise at 80° arm elevation
Number of subjects: 12
Study 29684979 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported exercise at 120° arm elevation
Number of subjects: 12
Study 29684979 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported exercise at 80° arm elevation
Number of subjects: 12
Study 29684979 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported exercise at 120° arm elevation
Number of subjects: 12
Study 29684979 — intervention group
Group type: EXPERIMENTAL
Intervention: 120° arm elevation (both unsupported and supported)
Number of subjects: 12
Study 29684979 — intervention group
Group type: COMPARATOR
Intervention: 80° arm elevation (both unsupported and supported)
Number of subjects: 12
Study 27981528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g Bayaspirin (ASA II group) administered at draught before sleep
Number of subjects: 150
Study 27981528 — intervention group
Group type: COMPARATOR
Intervention: 30 mg Adalat (control group) administered orally once a day
Number of subjects: 150
Study 27981528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g Bayaspirin (ASA I group) administered at draught in the morning
Number of subjects: 150
Study 24571870 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5% ropivacaine injected peri‐incisionally with pulmonary recruitment manoeuvre (Group 2)
Number of subjects: 60
Study 24571870 — intervention group
Group type: COMPARATOR
Intervention: 20 ml of 0.5% ropivacaine injected peri‐incisionally without pulmonary recruitment manoeuvre (Group 1)
Number of subjects: 60
Study 24571870 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (ropivacaine with pulmonary recruitment manoeuvre)
Number of subjects: 60
Study 23259913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (daily sessions)
Number of subjects: 89
Study 23259913 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 89
Study 23259913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (for compliant women)
Number of subjects: 89
Study 23259913 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-compliant women)
Number of subjects: 89
Study 20139780 — intervention group
Group type: COMPARATOR
Intervention: Strength Training (ST)
Number of subjects: 24
Study 20139780 — intervention group
Group type: COMPARATOR
Intervention: Power Training (PT)
Number of subjects: 24
Study 20139780 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 18412873 — intervention group
Group type: EXPERIMENTAL
Intervention: Two passes of microdermabrasion (MDA)
Number of subjects: 10
Study 18412873 — intervention group
Group type: EXPERIMENTAL
Intervention: Three passes of microdermabrasion (MDA)
Number of subjects: 10
Study 16109056 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 20 mg
Number of subjects: 613
Study 16109056 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 613
Study 16109056 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg (mild pain intensity)
Number of subjects: 613
Study 16109056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 11823892 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cocaine (0, 6, 12, or 25 mg cocaine base, depending on the session) administered during the follicular phase.
Number of subjects: 11
Study 11823892 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cocaine (0, 6, 12, or 25 mg cocaine base, depending on the session) administered during the luteal phase.
Number of subjects: 11
Study 10459958 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg tablets), one tablet twice daily until the onset of labour, one tablet at onset of labour, and one tablet every 3 h until delivery
Number of subjects: 280
Study 10459958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 10459958 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg tablets)
Number of subjects: 280
Study 7617467 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MAG3 (300 MBq)
Number of subjects: 12
Study 7617467 — intervention group
Group type: COMPARATOR
Intervention: 123I‐OIH (37 MBq)
Number of subjects: 12
Study 2240110 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 229
Study 2240110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 576887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg/day of diethylstibestrol (DES)
Number of subjects: 523
Study 576887 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day of diethylstibestrol (DES)
Number of subjects: 523
Study 576887 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day of diethylstibestrol (DES)
Number of subjects: 523
Study 576887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/day of diethylstibestrol (DES)
Number of subjects: 523
Study 31277784 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care and educational seminar
Number of subjects: 255
Study 28333536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mom-Net intervention (8-session, Internet-facilitated cognitive-behavioral treatment)
Number of subjects: 266
Study 28333536 — intervention group
Group type: COMPARATOR
Intervention: Motivational Interviewing and Referral to Services (MIRS)
Number of subjects: 266
Study 25807815 — intervention group
Group type: COMPARATOR
Intervention: TVT-O alone
Number of subjects: 120
Study 25807815 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O with biofeedback pelvic floor electrical stimulation
Number of subjects: 120
Study 23160726 — intervention group
Group type: EXPERIMENTAL
Intervention: Imeglimin (1,500 mg twice a day)
Number of subjects: 156
Study 23160726 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to metformin (1,500-2,000 mg/day)
Number of subjects: 156
Study 21777737 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with CERTIFECT (fipronil, amitraz, and (S)-methoprene) applied 28 days prior to tick infestation
Number of subjects: 28
Study 21777737 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with CERTIFECT applied 21 days prior to tick infestation
Number of subjects: 28
Study 21777737 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with CERTIFECT applied 14 days prior to tick infestation
Number of subjects: 28
Study 21777737 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with CERTIFECT applied 7 days prior to tick infestation
Number of subjects: 28
Study 21777737 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (7 dogs)
Number of subjects: 28
Study 20635778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for psychosis, focusing on education about symptoms and cognitive models, including collaborative exploration of thoughts and schemas surrounding delusions and hallucinations.
Number of subjects: 0
Study 17083392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg)
Number of subjects: 101
Study 17083392 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (2 mg)
Number of subjects: 101
Study 15070001 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of motor and somatosensory function
Number of subjects: 64